oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Topoisomerase II-α expression in different cell cycle phases in fresh human breast carcinomas
Örebro University, School of Health and Medical Sciences.
Örebro University, School of Health and Medical Sciences.
Show others and affiliations
2002 (English)In: Modern Pathology, ISSN 0893-3952, E-ISSN 1530-0285, Vol. 15, no 5, 486-491 p.Article in journal (Refereed) Published
Abstract [en]

Topoisomerase II-alfa (topo IIalfa) is the key target enzyme for the topoisomerase inhibitor class of anti-cancer drugs. In normal cells, topo IIalfa is expressed predominantly in the S/G2/M phase of the cell cycle. In malignant cells, in vitro studies have indicated that the expression of topo IIalfa is both higher and less dependent on proliferation state in the cell. We studied fresh specimens from 50 cases of primary breast cancer. The expression of topo IIalfa in different cell cycle phases was analyzed with two-parameter flow cytometry using the monoclonal antibody SWT3D1 and propidium iodide staining. The expression of topo IIalfa was significantly higher in the S/G2/M phase of the cell cycle than in the G0/G1 phase in both DNA diploid and DNA nondiploid tumors. In 18 of 21 diploid tumors, and in 25 of 29 nondiploid tumors, >50% of the topo IIalfa–positive cells were in the G0/G1 phase. This significant expression of topo IIalfa in the G0/G1 phase of the cell cycle may have clinically important implications for treatment efficacy of topoisomerase II inhibitors.

Place, publisher, year, edition, pages
Baltimore: Lippincott Williams & Wilkins , 2002. Vol. 15, no 5, 486-491 p.
Keyword [en]
breast cancer, cell cycle, DNA flow cytometry, topoisomerase IIa
National Category
Medical and Health Sciences
Research subject
Medicine; Biomedicine
Identifiers
URN: urn:nbn:se:oru:diva-10515OAI: oai:DiVA.org:oru-10515DiVA: diva2:313640
Available from: 2010-04-27 Created: 2010-04-27 Last updated: 2016-08-10Bibliographically approved
In thesis
1. Biological markers in breast cancer and acute leukaemia with focus on drug resistance
Open this publication in new window or tab >>Biological markers in breast cancer and acute leukaemia with focus on drug resistance
2010 (English)Doctoral thesis, comprehensive summary (Other academic)
Place, publisher, year, edition, pages
Örebro: Örebro universitet, 2010. 68 p.
Series
Örebro Studies in Medicine, ISSN 1652-4063 ; 43
Keyword
Breast cancer, acute leukaemia, drug resistance, toposiomerase IIa, BCRP, HER2, SLC25A43, flow cytometry, real time PCR, whole genome screening
National Category
Medical and Health Sciences Cancer and Oncology
Research subject
Biomedicine
Identifiers
urn:nbn:se:oru:diva-10519 (URN)978-91-7668-724-6 (ISBN)
Public defence
2010-05-21, Bohmanssonsalen, Universitetssjukhuset, Örebro, 13:00 (Swedish)
Opponent
Supervisors
Available from: 2010-04-27 Created: 2010-04-27 Last updated: 2011-04-26Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Liljegren, GöranTidefelt, UlfKarlsson, Mats G.
By organisation
School of Health and Medical Sciences
In the same journal
Modern Pathology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Total: 260 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf